Subsequently, the original mouse version (IOR-T1) of itolizumab, a humanised mAb against human CD6 currently approved for the treatment of psoriasis [54] (Table 1), was assayed for topical treatment of cutaneous T-cell lymphoma (CTCL) skin lesions [55] (Table 1). This evidence concerns the gene CD6 and primary cutaneous T-cell non-Hodgkin lymphoma.